Understanding Posterior Cortical Atrophy (PCA)
At a Glance
Posterior cortical atrophy (PCA) is a rare brain syndrome that disrupts visual and spatial processing even when the eyes are healthy. It often reflects Alzheimer’s disease and is evaluated with visual-spatial testing, brain MRI, and sometimes amyloid or tau biomarkers.
If you are reading this, you may have spent months or even years visiting eye doctors, getting new eyeglass prescriptions that didn’t help, and being told your eyes are perfectly healthy while your world became increasingly difficult to navigate. This “diagnostic odyssey” is a common and frustrating experience for people with Posterior Cortical Atrophy (PCA) [1][2].
PCA is a rare neurodegenerative syndrome that affects the back part of the brain—the posterior regions—which are responsible for processing what your eyes see [3]. Unlike typical Alzheimer’s disease, which usually begins with memory loss, PCA begins with vision and spatial problems [4].
Why PCA is Often Mistaken for an Eye Problem
The reason you likely saw an optometrist or ophthalmologist first is that your symptoms felt purely visual. You may have experienced difficulty reading, trouble judging distances, or a strange feeling that you couldn’t “find” objects right in front of you [5][6].
However, in PCA, your eyes themselves may be structurally healthy, but the visual processing networks at the back of your brain are struggling to organize the images correctly [2]. Because standard eye exams focus on the health of the eye itself—checking your retina, optic nerve, and eye pressure—they often come back completely normal in PCA patients (though you may also have common eye conditions like cataracts alongside PCA) [6][7]. This leads to a delay in diagnosis because clinicians may not immediately suspect a brain-based cause for visual complaints [1].
The Biology of PCA
PCA is described as a clinico-radiological syndrome, which means it is defined by a specific set of clinical symptoms combined with characteristic findings on brain scans [3]. It is not a single disease itself, but rather a way that several different brain diseases can show up [8].
- The Alzheimer’s Connection: In one large international study, approximately 94% of cases were caused by Alzheimer’s disease pathology [8]. This involves the buildup of two proteins: amyloid and tau [8].
- Targeted Damage: While amyloid often spreads widely across the brain, tau tangles tend to concentrate in the back of the brain (occipital and parietal lobes) in PCA [9]. This specific concentration of tau is what causes the unique visual symptoms of PCA compared to the memory loss seen in more common forms of Alzheimer’s [10][11].
- Other Causes: In a minority of cases, other conditions like Lewy body disease, corticobasal degeneration, or prion disease can cause PCA symptoms [8][12].
Typical Age and Presentation
One of the most challenging aspects of PCA is that it often strikes earlier than other forms of dementia. The mean age when symptoms first begin is roughly 59 years old, and most people develop symptoms before age 65 [8][13].
Because it affects people in their 50s and 60s—years when many are still working or driving—the impact on daily life can be profound. Early signs often include:
- Reading difficulties: Words may seem to jump around or blur together [5].
- Object localization: Having trouble reaching for an object or finding something in a cluttered drawer [14].
- Simultanagnosia: An inability to see more than one object at a time or understand a whole scene even though you can see individual parts [15].
- Navigation issues: Getting lost in familiar places or having trouble judging the distance between cars while driving [5].
Reaching a Diagnosis
To diagnose PCA, doctors look for a combination of your clinical symptoms and specific findings on brain imaging.
- Clinical Evaluation: A neurologist or neuro-ophthalmologist will perform tests that look at your visual-spatial skills, such as asking you to copy complex drawings or describe what is happening in a busy picture [15][16].
- Structural MRI: Scans typically show atrophy (shrinking) in the back of the brain, particularly in the parietal and occipital lobes [17][18].
- Biomarkers: Tests like an amyloid PET scan, tau PET scan, or a lumbar puncture (spinal tap) can investigate if Alzheimer’s proteins are present, helping your care team determine the best way to manage the condition [8][9].
Understanding that your symptoms are real—and that they stem from changing visual processing in the brain rather than the eyes—is the first step toward getting the right support and care. Although the diagnosis can be overwhelming, it provides a name for the challenges you have been facing and opens the door to specialized treatments and therapies designed for visual processing disorders.
Common questions in this guide
Can PCA cause vision problems even when my eyes are healthy?
What are the early warning signs of posterior cortical atrophy?
How do doctors diagnose posterior cortical atrophy?
What can an MRI reveal when PCA is suspected?
Is posterior cortical atrophy always caused by Alzheimer’s disease?
What tests can show whether Alzheimer’s disease is behind PCA?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific tests will you use to evaluate my higher-order visual processing, such as my ability to see more than one object at a time or reach for objects accurately?
- 2.Given that my eye exams were normal, how does my brain MRI specifically show evidence of posterior cortical atrophy?
- 3.What biomarkers, like a PET scan or spinal fluid test, do you recommend to confirm if Alzheimer's pathology is the cause of my PCA?
- 4.Is my current treatment plan addressing the underlying Alzheimer's biology or focusing on managing my visual symptoms?
- 5.Should I be evaluated for other related conditions like Lewy body disease or corticobasal degeneration based on my symptoms?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (18)
- 1
Longitudinal Evolution of Posterior Cortical Atrophy: Diagnostic Delays, Overlapping Phenotypes, and Clinical Outcomes.
Shir D, Lee N, McCarter SJ, et al.
Neurology 2025; (104(9)):e213559 doi:10.1212/WNL.0000000000213559.
PMID: 40198862 - 2
[Posterior cortical atrophy-plus syndrome. A case report].
Saleh C, Seidl U, Stegentritt K, et al.
Fortschritte der Neurologie-Psychiatrie 2020; (88(8)):528-531 doi:10.1055/a-1149-2057.
PMID: 32634845 - 3
Posterior Cortical Atrophy.
Schott JM, Crutch SJ
Continuum (Minneapolis, Minn.) 2019; (25(1)):52-75 doi:10.1212/CON.0000000000000696.
PMID: 30707187 - 4
Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event-based model of disease progression.
Firth NC, Primativo S, Brotherhood E, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2020; (16(7)):965-973 doi:10.1002/alz.12083.
PMID: 32489019 - 5
Pop-out illusion as the initial presentation of posterior cortical atrophy.
Prabhakar TA
Neurocase 2021; (27(3)):266-269 doi:10.1080/13554794.2021.1929333.
PMID: 34128452 - 6
Homonymous Hemianopsia Due to Posterior Cortical Atrophy.
Pellegrini F, Lee AG, Zucchetta P
Neuro-ophthalmology (Aeolus Press) 2017; (41(3)):154-158 doi:10.1080/01658107.2016.1278556.
PMID: 28512507 - 7
[Posterior cortical atrophy presenting with agraphia for kanji and statokinetic dissociation (Riddoch phenomenon): a case report].
Maruta K, Shiomi K
Rinsho shinkeigaku = Clinical neurology 2025; (65(6)):416-423 doi:10.5692/clinicalneurol.cn-002036.
PMID: 40399055 - 8
Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
Chapleau M, La Joie R, Yong K, et al.
The Lancet. Neurology 2024; (23(2)):168-177 doi:10.1016/S1474-4422(23)00414-3.
PMID: 38267189 - 9
Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET.
La Joie R, Visani AV, Lesman-Segev OH, et al.
Neurology 2021; (96(5)):e650-e661 doi:10.1212/WNL.0000000000011270.
PMID: 33262228 - 10
Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A, Iaccarino L, Edwards L, et al.
Brain : a journal of neurology 2022; (145(2)):713-728 doi:10.1093/brain/awab294.
PMID: 34373896 - 11
Functional network contributions to longitudinal tau spread in Posterior Cortical Atrophy.
Katsumi Y, Eckbo R, McGinnis SM, et al.
NPJ dementia 2026; (2(1)):46 doi:10.1038/s44400-026-00101-y.
PMID: 42327427 - 12
Posterior Cortical Atrophy Masked by a Pituitary Macroadenoma: Diagnostic Challenges in the Setting of Dual Visual Pathology.
Bloomfield AS, Mori AM
Cureus 2025; (17(12)):e99908 doi:10.7759/cureus.99908.
PMID: 41445987 - 13
Posterior cortical atrophy: clinical, neuroimaging, and neuropathological features.
Best J, Chapleau M, Rabinovici GD
Expert review of neurotherapeutics 2023; (23(3)):227-236 doi:10.1080/14737175.2023.2190885.
PMID: 36920752 - 14
Posterior cortical atrophy: Primary occipital variant.
Shir D, Graff-Radford J, Machulda MM, et al.
European journal of neurology 2022; (29(7)):2138-2143 doi:10.1111/ene.15327.
PMID: 35298068 - 15
Consensus recommendations for clinical assessment tools for the diagnosis of posterior cortical atrophy syndrome from the Atypical AD PIA of ISTAART.
Pelak VS, Tang-Wai DF, Boeve BF, et al.
Alzheimer's & dementia (Amsterdam, Netherlands) 2023; (15(3)):e12474 doi:10.1002/dad2.12474.
PMID: 39329067 - 16
Visual signs and symptoms in patients with the visual variant of Alzheimer disease.
Kaeser PF, Ghika J, Borruat FX
BMC ophthalmology 2015; (15()):65 doi:10.1186/s12886-015-0060-9.
PMID: 26122482 - 17
Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy.
Firth NC, Primativo S, Marinescu RV, et al.
Brain : a journal of neurology 2019; (142(7)):2082-2095 doi:10.1093/brain/awz136.
PMID: 31219516 - 18
A Pilot Study on Clinical and Neuroimaging Characteristics of Chinese Posterior Cortical Atrophy: Comparison with Typical Alzheimer's Disease.
Wang XD, Lu H, Shi Z, et al.
PloS one 2015; (10(8)):e0134956 doi:10.1371/journal.pone.0134956.
PMID: 26267071
This page explains posterior cortical atrophy and its diagnostic testing for informational purposes only and does not constitute medical advice. A neurologist or neuro-ophthalmologist should interpret your symptoms, scans, and test results.
Get notified when new evidence is published on Posterior cortical atrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.